JNJ.NEO Johnson & Johnson CDR (CAD Hedged)

Healthcare Drug Manufacturers - General NEO Exchange
34.84 CAD
Close of Oct 30, 2026
23.70 35.66
Market cap
CAD 909B
P/E
23.9x
P/B
7.12x
ROE
18.0%
Dividend yield
2.49%
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JNJ.NEO undervalued?

Graham number
Price34.84
Graham value12.66
Premium175.2%

JNJ.NEO trades 175.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Johnson & Johnson CDR (CAD Hedged) fundamental analysis

15 of 22 checks passed

ROE 1/2

Moderate return on equity (18.0%), between 10% and 20%.

ROA 0/1

Return on assets (7.4%) is below the industry median (7.4%).

Profit Consistency 2/2

Profitable for 6 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (90.5%) is above the 5-year average (14.8% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (90.5%) is below the industry median (90.5%).

Revenue Growth 1/2

Revenue grew 5.6% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 1/2

Moderate debt to equity (43.9%), up to 100%.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 17.6x against interest expense, well covered.

PE vs Market 0/1

PE (25.2x) is above the market median (20.3x).

PE vs Industry 0/1

PE (25.2x) is above the industry median (25.0x).

PBV 1/1

Price to book (7.5x) is below the industry median (8.1x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 188.7, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.70, above 1.

Dividend Yield 1/2

Dividend yield (1.8%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 6 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 46.2%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Johnson & Johnson CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Johnson & Johnson CDR (CAD Hedged)

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience…

Full company profile